Korean Circulation Journal

  • 제54권9호
  • /
  • Pages.565-576
  • /
  • 2024
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease: K-ELUVIA Registry

  • Joongmin Kim (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Young-Guk Ko (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Seung-Jun Lee (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Chul-Min Ahn (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Seung-Woon Rha (Division of Cardiology, Cardiovascular Center, Korea University Guro Hospital) ;
  • Cheol Ung Choi (Division of Cardiology, Cardiovascular Center, Korea University Guro Hospital) ;
  • Pil-Ki Min (Division of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Jong Kwan Park (Division of Cardiology, National Health Insurance Service Ilsan Hospital) ;
  • Ji-Yong Jang (Division of Cardiology, National Health Insurance Service Ilsan Hospital) ;
  • Young Jin Youn (Division of Cardiology, Wonju Severance Hospital, Yonsei University Wonju College of Medicine) ;
  • Tae-Soo Kang (Division of Cardiology, Department of Internal Medicine, Dankook University College of Medicine) ;
  • Chang-Hwan Yoon (Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Donghoon Choi (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine)
  • 투고 : 2024.01.25
  • 심사 : 2024.04.17
  • 발행 : 2024.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: The K-ELUVIA study aimed to investigate the clinical effectiveness and safety of EluviaTM, a polymer-coated, paclitaxel-eluting stent, for femoropopliteal artery disease using data from a prospective Korean multicenter registry. Methods: A total of 105 patients with femoropopliteal artery disease who received endovascular treatment (EVT) with EluviaTM stents at 7 Korean sites were enrolled in a prospective cohort and followed for 2 years. The primary endpoint was the 2-year clinical patency. The secondary endpoint was 2-year freedom from clinically driven target lesion revascularization (TLR). Results: Mean patient age was 68.2±10.4 years, and most patients (82.7%) were male. Mean lesion length was 168.3±117.6 mm. Chronic total occlusion was found in 57.7% of patients. Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) type C or D lesions were present in 46.1% of patients. Procedural success was achieved in 99.0% of patients. The clinical patency rate was 84.4% at 1 year after EVT and 76.3% at 2 years post-EVT. The freedom from TLR rate was 89.1% at 1 year after EVT and 79.1% at 2 years post-EVT. Chronic total occlusion (hazard ratio [HR], 3.53; 95% confidence interval [CI], 1.08-11.67; p=0.039) and smaller mean stent diameter (HR, 0.40; 95% CI, 0.16-0.98; p=0.044) were identified as independent predictors of loss of clinical patency at 2 years. Conclusions: The K-ELUVIA study demonstrated favorable 2-year clinical effectiveness and safety outcomes of Eluvia stent for femoropopliteal artery lesions in real-world practice.

키워드

과제정보

We would like to thank Editage and ChatGPT for their linguistic assistance in improving the grammar and spelling of this manuscript.

참고문헌

  1. Ko YG, Ahn CM, Min PK, et al. Baseline characteristics of a retrospective patient cohort in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry. Korean Circ J 2017;47:469-76.
  2. Poulson W, Kamenskiy A, Seas A, Deegan P, Lomneth C, MacTaggart J. Limb flexion-induced axial compression and bending in human femoropopliteal artery segments. J Vasc Surg 2018;67:607-13.
  3. Acin F, de Haro J, Bleda S, Varela C, Esparza L. Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials. J Endovasc Ther 2012;19:585-95.
  4. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99.
  5. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
  6. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61:2417-27.
  7. Dake MD, Ansel GM, Bosiers M, et al. Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol 2020;43:8-19.
  8. Kichikawa K, Ichihashi S, Yokoi H, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 2-year results. Cardiovasc Intervent Radiol 2019;42:358-64.
  9. Iida O, Takahara M, Soga Y, et al. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv 2016;9:828-34. 
  10. Iida O, Takahara M, Soga Y, et al. 1-Year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv 2015;8:1105-12.
  11. Gray WA, Keirse K, Soga Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018;392:1541-51.
  12. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 2014;83:E212-20.
  13. Goueffic Y, Torsello G, Zeller T, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial. Circulation 2022;146:1564-76.
  14. Muller-Hulsbeck S, Benko A, Soga Y, et al. Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drugcoated stent. Cardiovasc Intervent Radiol 2021;44:368-75.
  15. Iida O, Takahara M, Soga Y, et al. 1-Year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv 2022;15:630-8.
  16. Stavroulakis K, Torsello G, Bosiers M, Argyriou A, Tsilimparis N, Bisdas T. 2-Year outcomes of the Eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions. JACC Cardiovasc Interv 2021;14:692-701.
  17. Ichihashi S, Takahara M, Yamaoka T, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: results of the ULTIMATE study. Eur J Vasc Endovasc Surg 2022;64:359-66.
  18. Dake MD, Fanelli F, Lottes AE, et al. Prediction model for freedom from TLR from a multi-study analysis of long-term results with the Zilver PTX drug-eluting peripheral stent. Cardiovasc Intervent Radiol 2021;44:196-206.
  19. Tsujimura T, Iida O, Asai M, et al. Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern. CVIR Endovasc 2021;4:56.
  20. Bisdas T, Beropoulis E, Argyriou A, Torsello G, Stavroulakis K. 1-Year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty. JACC Cardiovasc Interv 2018;11:957-66.
  21. Soga Y, Ando K. "Low Echoic Area" around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease. SAGE Open Med Case Rep 2021;9:2050313X211014519.
  22. Holden A, Goueffic Y, Gray WA, Davis EJ, Weinberg I, Jaff MR. Hypoechoic halo imaging findings following femoropopliteal artery stent implantation: risk factors and clinical outcomes. JACC Cardiovasc Interv 2023;16:1654-64.